Last updated: August 7, 2026
Dibasic potassium phosphate, also called dipotassium hydrogen phosphate or K2HPO4, is a mature inorganic pharmaceutical excipient used primarily as a buffering agent, pH adjuster, nutrient, and formulation stabilizer. Its financial profile is driven by manufacturing scale, phosphate and potassium input costs, grade qualification, packaging, and supply reliability rather than patent exclusivity.
Public financial filings do not separately report revenue or profit for pharmaceutical-grade dibasic potassium phosphate. Market estimates that combine pharmaceutical, biotechnology, food, laboratory, and industrial grades should not be treated as pharmaceutical-excipient revenue.
What is dibasic potassium phosphate used for in pharmaceutical formulations?
Dibasic potassium phosphate is used to control pH, provide phosphate ions, and maintain formulation stability. It is commonly supplied as anhydrous material or hydrated forms.
| Attribute |
Pharmaceutical relevance |
| Chemical name |
Dipotassium hydrogen phosphate |
| Formula |
K2HPO4 |
| CAS number |
7758-11-4 for anhydrous material |
| Anhydrous molecular weight |
174.18 g/mol |
| Common hydrated form |
Dipotassium hydrogen phosphate trihydrate |
| Primary functions |
Buffering agent, pH modifier, tonicity contributor, nutrient |
| Typical applications |
Parenteral products, oral liquids, biologic media, cell culture, diagnostic products |
| Compendial status |
Covered in major pharmaceutical and chemical quality systems, subject to monograph and supplier specifications |
| Patent status |
No meaningful composition-of-matter exclusivity for the commodity excipient |
The compound is often used with monobasic potassium phosphate, sodium phosphate salts, or other buffering systems. In biologics manufacturing, it can be part of cell-culture media, process buffers, purification buffers, and formulation development.
The commercial value of the material depends on its grade. Pharmaceutical and biopharmaceutical customers may require low endotoxin, low bioburden, defined elemental impurity limits, controlled particle properties, and extensive documentation. Laboratory-grade and industrial-grade products generally do not meet the same qualification requirements.
How large is the pharmaceutical-grade dibasic potassium phosphate market?
There is no authoritative public figure for global pharmaceutical-grade dibasic potassium phosphate revenue. Published market reports commonly aggregate several categories:
- Potassium phosphate products
- Pharmaceutical excipients
- Laboratory reagents
- Cell-culture media
- Food additives
- Fertilizer and industrial phosphate products
- Multiple phosphate salts, including monobasic and tribasic forms
Those categories have different pricing, customers, regulatory requirements, and growth rates. A pharmaceutical-excipient market figure that does not isolate dibasic potassium phosphate is not a reliable measure of this product’s revenue pool.
The addressable pharmaceutical market is likely small relative to the global phosphate chemicals market, but it carries higher unit economics. Pharmaceutical-grade material is sold in smaller lots with documentation, testing, validation support, and controlled packaging. Biopharmaceutical-grade products can command higher prices when supplied with low-endotoxin certificates, animal-origin statements, change-control commitments, and lot-specific analytical data.
What drives demand for dibasic potassium phosphate?
Biologics and cell-culture manufacturing
Biologics manufacturing is the strongest structural demand driver. Phosphate salts are used in media and buffers associated with monoclonal antibodies, recombinant proteins, vaccines, viral vectors, and other biological products.
Demand is not directly proportional to drug sales. A single commercial biologic may consume relatively modest quantities of dibasic potassium phosphate compared with high-volume industrial applications. The value arises from qualification requirements and the cost of a supply interruption, not from large mass consumption.
Parenteral and oral formulations
Dibasic potassium phosphate is used in injectable and oral formulations where pH control and phosphate buffering are required. Its use is limited by formulation-specific considerations, including:
- Compatibility with calcium and magnesium ions
- Risk of precipitation
- Osmolality constraints
- Route-of-administration requirements
- Stability across storage conditions
- Sterilization and aseptic-processing requirements
In injectable products, suppliers must provide stronger control over impurities, microbial quality, and manufacturing consistency than suppliers serving non-pharmaceutical markets.
Diagnostic and laboratory products
The compound is used in diagnostic reagents, analytical buffers, and laboratory media. This segment supports recurring demand but has more fragmented purchasing and greater price competition than regulated drug manufacturing.
Food and industrial substitution
Food, fermentation, agricultural, and industrial demand can affect upstream phosphate economics. These markets provide scale for producers but also create competing outlets for production capacity. Pharmaceutical customers generally cannot substitute industrial-grade material without a new qualification process.
How does the dibasic potassium phosphate supply chain work?
The supply chain begins with phosphate rock or other phosphorus feedstocks, potassium-containing inputs, and chemical conversion processes. Producers then crystallize, dry, mill, package, and test the material according to the targeted grade.
| Supply-chain stage |
Main economic issue |
| Phosphate feedstock |
Exposure to phosphate-rock and phosphoric-acid pricing |
| Potassium input |
Exposure to potassium salt and potash economics |
| Chemical conversion |
Energy, yield, and process-capacity costs |
| Crystallization and drying |
Particle form, hydration state, and consistency |
| Pharmaceutical testing |
Assay, impurities, endotoxin, microbial, and elemental testing |
| Packaging |
Contamination control and lot traceability |
| Distribution |
Freight, regional inventory, and qualification support |
The product is chemically simple, but pharmaceutical supply is not interchangeable at the customer level. A drug manufacturer may qualify a specific site, process, grade, and packaging configuration. Switching suppliers can require comparative testing, stability assessment, change-control review, and regulatory documentation.
What is the financial trajectory for dibasic potassium phosphate?
The financial trajectory is best characterized as stable, low-growth, and margin-segmented rather than high-growth.
| Financial factor |
Expected effect |
| Pharmaceutical demand |
Supports steady recurring volume |
| Biologics production |
Supports premium-grade demand |
| Commodity phosphate pricing |
Creates input-cost volatility |
| Energy and freight |
Affects delivered cost and gross margin |
| Supplier qualification |
Protects incumbent relationships |
| Product standardization |
Limits long-term pricing power |
| Low patent barriers |
Encourages supplier competition |
| Documentation and quality systems |
Supports premium pricing |
| Customer concentration |
Can create volume and negotiation risk |
Revenue growth generally comes from higher biopharmaceutical production, geographic expansion, additional qualified customers, and migration from laboratory-grade to pharmaceutical-grade supply. Price increases usually reflect raw-material inflation, energy costs, freight, packaging, or quality-system investments.
The product does not have the commercial profile of a patented API or a specialty excipient with proprietary delivery technology. Unit prices are vulnerable to competitive bidding, especially where customers have approved multiple suppliers. Gross margins are higher for validated, low-endotoxin, or biopharmaceutical grades than for bulk commodity material.
Public-company disclosures from diversified suppliers typically place this activity inside broader segments such as laboratory products, life-science products, pharmaceutical ingredients, or industrial chemicals. Investors therefore cannot calculate dibasic potassium phosphate revenue, EBITDA, or market share from company filings alone.
Which companies supply pharmaceutical-grade dibasic potassium phosphate?
The commercial supply base includes diversified life-science distributors, laboratory reagent companies, pharmaceutical-ingredient suppliers, and regional chemical manufacturers. Commonly encountered suppliers and brands include:
- Merck and Sigma-Aldrich
- Thermo Fisher Scientific
- Avantor and J.T.Baker
- Spectrum Chemical
- FUJIFILM Irvine Scientific and other media suppliers where phosphate salts are incorporated into formulation systems
- Regional manufacturers serving China, India, Europe, and North America
The presence of a supplier in a laboratory catalog does not establish that it supplies material suitable for commercial drug manufacturing. Customers must distinguish among ACS, analytical, laboratory, USP/NF, EP, JP, GMP, low-endotoxin, and cell-culture grades.
Supplier competitiveness is determined by:
- Compendial compliance
- Manufacturing-site qualification
- Batch consistency
- Supply continuity
- Change-notification procedures
- Regulatory documentation
- Global distribution
- Ability to support audits and deviations
What patents protect dibasic potassium phosphate?
No commercially material patent estate protects dibasic potassium phosphate as a chemical entity. The compound has long been known and is a conventional inorganic salt.
Patent protection may exist around a specific drug formulation, buffer system, manufacturing process, media composition, or combination containing dibasic potassium phosphate. Those rights would generally protect the formulation or process, not the excipient itself.
| IP category |
Relevance |
| Composition-of-matter patent |
No meaningful current protection for the basic compound |
| Formulation patent |
Possible when the salt is part of a defined drug product |
| Method-of-use patent |
Possible for a specific therapeutic product, not the excipient generally |
| Manufacturing patent |
Possible for a specialized process or particle form |
| Trade secret |
Relevant to process control, impurity removal, and yield |
| Trademark |
Relevant to supplier branding, not chemical exclusivity |
There is no standard Orange Book listing for dibasic potassium phosphate as an excipient. It is not an FDA-approved active pharmaceutical ingredient with an independent reference-listed drug. Paragraph IV litigation and generic-entry disputes therefore do not apply to the excipient on a standalone basis.
What is the FDA and regulatory status of dibasic potassium phosphate?
Dibasic potassium phosphate is used as an inactive ingredient in drug products and as a component in pharmaceutical manufacturing systems. FDA’s Inactive Ingredient Database provides a reference point for prior use in approved drug products, dosage forms, and routes of administration. Inclusion in the database does not eliminate the need for product-specific justification, quality controls, and formulation assessment.
Relevant regulatory controls include:
- USP/NF or other applicable compendial specifications
- Identity, assay, and impurity testing
- Elemental impurity assessment under ICH Q3D
- Microbial and endotoxin controls for relevant applications
- Residual solvent controls where applicable
- Supplier qualification and audit history
- Change-control and notification procedures
- Container-closure and storage controls
- Traceability to the manufacturing site and lot
For biologics, the material may be evaluated under the sponsor’s raw-material control strategy and may require more extensive documentation than a conventional oral-solid-dose excipient.
What formulation patents and manufacturing barriers affect the market?
The main barriers are operational and regulatory rather than patent-based.
Formulation barriers
Phosphate salts can interact with divalent cations and affect precipitation, aggregation, or stability. In biologics, phosphate concentration and pH can influence protein solubility and particle formation. A change in buffer composition may require stability and comparability work.
Manufacturing barriers
Manufacturers must control hydration state, crystal form, particle-size distribution, moisture, trace metals, and microbial quality. A supplier that changes drying conditions, raw materials, or packaging can create a customer qualification event.
Regulatory barriers
The cost of switching suppliers is modest compared with switching an API supplier, but it is not zero. The customer may need to update specifications, perform equivalence testing, assess extractables and leachables, revise manufacturing documentation, and notify regulators where the change affects a registered product.
When does dibasic potassium phosphate lose exclusivity?
Dibasic potassium phosphate does not have a conventional exclusivity expiration date. Its composition is in the public domain, and market access is not controlled by an Orange Book patent, regulatory exclusivity period, or biosimilar reference-product framework.
Commercial defensibility comes from supplier qualification, manufacturing reliability, quality records, customer relationships, and specialized grades. These advantages can persist after a customer qualification, but they are not legal exclusivity rights.
What generic-entry risks exist for products containing dibasic potassium phosphate?
Generic-entry risk applies to the finished drug product, not to dibasic potassium phosphate itself. A generic manufacturer can generally source the excipient from an approved supplier or qualify an alternative source, subject to the product’s formulation and regulatory requirements.
Risk increases where:
- The reference product uses a narrow pH range
- Phosphate concentration affects stability
- The dosage form is sterile or injectable
- The product contains calcium or magnesium
- The formulation is a biologic or complex mixture
- The supplier has a proprietary grade or limited-source qualification
- The finished product has formulation patents or method-of-use patents
The excipient rarely blocks generic entry by itself. It can create technical execution risk when formulation performance depends on tight control of buffer concentration, impurity profile, or particle characteristics.
How does dibasic potassium phosphate compare with competing phosphate buffers?
| Excipient |
Main advantage |
Main limitation |
| Dibasic potassium phosphate |
Potassium-based buffering and good water solubility |
Potassium load and precipitation concerns |
| Monobasic potassium phosphate |
Acidic phosphate component for buffer systems |
Usually used with a basic phosphate salt |
| Dibasic sodium phosphate |
Broad pharmaceutical use and established supply |
Adds sodium load |
| Monobasic sodium phosphate |
Flexible sodium phosphate buffering |
Sodium-related formulation constraints |
| Histidine |
Common in biologic formulations |
Higher cost and formulation-specific stability |
| Citrate salts |
Useful buffering range and broad availability |
Can interact with metals and affect tolerability |
| Acetate salts |
Useful for selected biologic and parenteral products |
Narrower application fit in some formulations |
Selection depends on target pH, ionic strength, route, excipient compatibility, regulatory history, and product stability. No single buffer salt dominates across all pharmaceutical applications.
What is the investment outlook for dibasic potassium phosphate suppliers?
The investment case is defensive rather than growth-oriented. Attractive characteristics include recurring demand, low technological obsolescence, and customer switching costs created by qualification. Constraints include limited differentiation, weak patent protection, commodity input exposure, and limited standalone reporting.
Supplier earnings are most sensitive to:
- Contract repricing
- Phosphate and potassium input costs
- Energy prices
- Freight rates
- Capacity utilization
- Quality-related batch failures
- Biopharmaceutical production volumes
- Inventory destocking by distributors
- Currency movements in cross-border supply
A supplier with integrated raw-material access, multiple qualified manufacturing sites, low-endotoxin capability, and strong distribution is better positioned than a producer competing only on bulk price.
Key Takeaways
- Dibasic potassium phosphate is a mature, standardized pharmaceutical excipient.
- Its principal uses are buffering, pH adjustment, and nutrient support in drugs, biologics, media, and diagnostics.
- Public sources do not isolate pharmaceutical-grade dibasic potassium phosphate revenue or profitability.
- Growth is linked mainly to biologics, cell culture, sterile formulations, and regional pharmaceutical manufacturing.
- Pharmaceutical-grade material commands a premium because of testing, documentation, qualification, and supply continuity.
- The compound has no meaningful standalone patent or regulatory exclusivity.
- Orange Book listings, Paragraph IV challenges, biosimilar litigation, and generic litigation do not apply to the excipient itself.
- The major barriers are formulation compatibility, supplier qualification, impurity control, and manufacturing consistency.
- Financial performance is likely to remain stable with modest volume growth and periodic price movement tied to raw materials and logistics.
- Supplier quality systems and reliable capacity matter more than patent ownership.
FAQs About Dibasic Potassium Phosphate
Is dibasic potassium phosphate an API or an excipient?
In pharmaceutical formulations, dibasic potassium phosphate is generally an excipient or process material. It is used to control pH, provide phosphate ions, or support cell-culture and manufacturing operations.
Is dibasic potassium phosphate listed in the Orange Book?
No standalone Orange Book listing applies to dibasic potassium phosphate as an excipient. Any relevant patent listing would relate to a finished drug product containing the compound.
Can pharmaceutical manufacturers switch dibasic potassium phosphate suppliers?
Yes, but the change normally requires supplier qualification, comparative testing, quality review, and assessment of regulatory impact. Sterile, biologic, and injectable products generally require greater scrutiny.
Does dibasic potassium phosphate have biosimilar risk?
No. Biosimilar risk applies to biologic drug products, not to this inorganic excipient. The material may be used in biologics manufacturing, but it is not itself a biologic reference product.
What is the difference between anhydrous and hydrated dibasic potassium phosphate?
They differ in water content, molecular weight, density, and potentially processing behavior. The selected form must match the formulation calculation, specification, manufacturing process, and validated supplier material.
References
-
European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia (11th ed.). Council of Europe.
-
International Council for Harmonisation. (2019). ICH Q3D(R2): Guideline for elemental impurities. https://www.ich.org
-
Merck. (2024). Dipotassium hydrogen phosphate product information. Merck KGaA.
-
U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/sda/sdWelcome.cfm
-
U.S. Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
